Stanley R. Frankel

Dr. Stanley R. Frankel (M.D.) is Chief Medical Officer at Cytovia Therapeutics and Adjunct Professor of Medicine at the Division of Hematology/Oncology at Columbia University’s Vagelos College of Physicians and Surgeons, and Consultant to the world’s most innovative companies developing immuno-oncology and cellular therapies, drugs and compounds. Dr. Frankel sits on the Board of Directors and the Science and Technology Committee of Precision BioSciences, Inc. where he supports the development, approval and commercial deployment of advanced gene correction therapies.

Dr. Frankel is a leading academic and industry expert in the research, clinical development, and commercialization of cellular therapies. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies including acute lymphoblastic leukemia, multiple myeloma, and lymphoma.

Dr. Frankel has held the highest executive and leadership positions at Bristol-Myers Squibb (BMS), Celgene, Merck, AMGEN, Hoffmann-LA Roche, and others; he has also served on steering/development committees with JW Therapeutics, Jounce Therapeutics, Astra-Zeneca/Medimmune, Juno Therapeutics, and BeiGene.

Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University, and has been a board-certified licensed physician since 1986. He completed his residency at Mount Sinai Hospital and his fellowship at Memorial Sloan Kettering Cancer Center, where he was Chief Fellow. Frankel has held academic and clinical appointments at Roswell Park Cancer Institute, Georgetown University, and the University of Maryland.